1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exercise Training Preserves Myocardial Strain and Improves Exercise Tolerance in Doxorubicin-Induced Cardiotoxicity

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Doxorubicin causes cardiotoxicity and exercise intolerance. Pre-conditioning exercise training seems to prevent doxorubicin-induced cardiac damage. However, the effectiveness of the cardioprotective effects of exercise training concomitantly with doxorubicin treatment remains largely unknown. To determine whether low-to-moderate intensity aerobic exercise training during doxorubicin treatment would prevent cardiotoxicity and exercise intolerance, we performed exercise training concomitantly with chronic doxorubicin treatment in mice. Ventricular structure and function were accessed by echocardiography, exercise tolerance by maximal exercise test, and cardiac biology by histological and molecular techniques. Doxorubicin-induced cardiotoxicity, evidenced by impaired ventricular function, cardiac atrophy, and fibrosis. Exercise training did not preserve left ventricular ejection fraction or reduced fibrosis. However, exercise training preserved myocardial circumferential strain alleviated cardiac atrophy and restored cardiomyocyte cross-sectional area. On the other hand, exercise training exacerbated doxorubicin-induced body wasting without affecting survival. Finally, exercise training blunted doxorubicin-induced exercise intolerance. Exercise training performed during doxorubicin-based chemotherapy can be a valuable approach to attenuate cardiotoxicity.

          Related collections

          Most cited references55

          • Record: found
          • Abstract: not found
          • Article: not found

          Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

            Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS). Here we show that cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation. Furthermore, cardiomyocyte-specific deletion of Top2b protects mice from the development of doxorubicin-induced progressive heart failure, suggesting that doxorubicin-induced cardiotoxicity is mediated by topoisomerase-IIβ in cardiomyocytes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cancer-related fatigue--mechanisms, risk factors, and treatments.

              Fatigue is one of the most common adverse effects of cancer that might persist for years after treatment completion in otherwise healthy survivors. Cancer-related fatigue causes disruption in all aspects of quality of life and might be a risk factor of reduced survival. The prevalence and course of fatigue in patients with cancer have been well characterized and there is growing understanding of the underlying biological mechanisms. Inflammation seems to have a key role in fatigue before, during, and after cancer-treatment. However, there is a considerable variability in the presentation of cancer-related fatigue, much of which is not explained by disease-related or treatment-related characteristics, suggesting that host factors might be important in the development and persistence of this symptom. Indeed, longitudinal studies have identified genetic, biological, psychosocial, and behavioural risk factors associated with cancer-related fatigue. Although no current gold-standard treatment for fatigue is available, a variety of intervention approaches have shown beneficial effects in randomized controlled trials, including physical activity, psychosocial, mind-body, and pharmacological treatments. This Review describes the mechanisms, risk factors, and possible interventions for cancer-related fatigue, focusing on recent longitudinal studies and randomized trials that have targeted fatigued patients.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Cardiovasc Med
                Front Cardiovasc Med
                Front. Cardiovasc. Med.
                Frontiers in Cardiovascular Medicine
                Frontiers Media S.A.
                2297-055X
                01 April 2021
                2021
                : 8
                : 605993
                Affiliations
                [1] 1Faculdade de Medicina, Heart Institute (InCor), Hospital das Clínicas, Universidade de São Paulo , São Paulo, Brazil
                [2] 2School of Physical Education and Sport, Universidade de São Paulo , São Paulo, Brazil
                [3] 3Faculdade de Medicina, Cancer Institute of the State of São Paulo (ICESP), Hospital das Clínicas, Universidade de São Paulo , São Paulo, Brazil
                [4] 4Centro de Oncologia Molecular, Hospital Sírio-Libanês , São Paulo, Brazil
                Author notes

                Edited by: Jun-ichi Abe, University of Texas MD Anderson Cancer Center, United States

                Reviewed by: Martino Deidda, University of Cagliari, Italy; Christian Cadeddu Dessalvi, University of Cagliari, Italy

                *Correspondence: Igor L. Gomes-Santos igomesdossantos@ 123456mgh.harvard.edu

                This article was submitted to Cardio-Oncology, a section of the journal Frontiers in Cardiovascular Medicine

                †Present address: Igor L. Gomes-Santos, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States

                Article
                10.3389/fcvm.2021.605993
                8047409
                33869297
                3784def0-77fb-4d1a-9fa9-b2e881fea46a
                Copyright © 2021 Gomes-Santos, Jordão, Passos, Brum, Oliveira, Chammas, Camargo and Negrão.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 14 September 2020
                : 01 March 2021
                Page count
                Figures: 6, Tables: 2, Equations: 0, References: 55, Pages: 12, Words: 7208
                Funding
                Funded by: Fundação de Amparo à Pesquisa do Estado de São Paulo 10.13039/501100001807
                Award ID: #2015/22814-5
                Categories
                Cardiovascular Medicine
                Original Research

                exercise,cardiac function,speckle tracking,doxorubicin,cardiotoxicity,fatigue

                Comments

                Comment on this article